Nuveen
HRMY icon

Nuveen’s Harmony Biosciences HRMY Stock Holding History

Nuveen’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.58M Buy
91,232
+1,354
+2% +$52.3K ﹤0.01% 2282
2026
Q2 		$3.27M Buy
89,878
+8,903
+11% +$281K ﹤0.01% 2325
2026
Q1 		$2.27M Sell
80,975
-2,129
-3% -$69.8K ﹤0.01% 2231
2025
Q4 		$3.11M Sell
83,104
-3,085
-4% -$101K ﹤0.01% 2117
2025
Q3 		$2.38M Sell
86,189
-5,094
-6% -$175K ﹤0.01% 2235
2025
Q2 		$2.88M Sell
91,283
-23,351
-20% -$751K ﹤0.01% 2136
2025
Q1 		$3.8M Sell
114,634
-97,717
-46% -$3.5M ﹤0.01% 2057
2024
Q4 		$7.31M Buy
212,351
+8,193
+4% +$282K ﹤0.01% 1775
2024
Q3 		$8.17M Hold
204,158
– – ﹤0.01% 1736
2024
Q2 		$6.16M Sell
204,158
-199,211
-49% -$5.99M ﹤0.01% 1841
2024
Q1 		$13.5M Buy
403,369
+677
+0.2% +$21.7K ﹤0.01% 1414
2023
Q4 		$13M Sell
402,692
-83,299
-17% -$2.33M ﹤0.01% 1419
2023
Q3 		$15.9M Buy
485,991
+79
+0% +$2.74K 0.01% 1177
2023
Q2 		$17.1M Buy
485,912
+116,784
+32% +$4.03M 0.01% 1179
2023
Q1 		$12.1M Sell
369,128
-6,874
-2% -$313K ﹤0.01% 1366
2022
Q4 		$20.7M Sell
376,002
-47,253
-11% -$2.6M 0.01% 1023
2022
Q3 		$18.7M Sell
423,255
-69,961
-14% -$3.41M 0.01% 1057
2022
Q2 		$24.1M Buy
493,216
+92,130
+23% +$4.15M 0.01% 921
2022
Q1 		$19.8M Buy
401,086
+17,092
+4% +$697K 0.01% 1204
2021
Q4 		$16.4M Sell
383,994
-77,272
-17% -$3.08M ﹤0.01% 1353
2021
Q3 		$17.7M Buy
461,266
+128,521
+39% +$4.14M 0.01% 1355
2021
Q2 		$9.39M Buy
332,745
+276,981
+497% +$8.31M ﹤0.01% 1909
2021
Q1 		$1.84M Buy
55,764
+45,607
+449% +$1.6M ﹤0.01% 2658
2020
Q4 		$367K Buy
+10,157
New +$410K ﹤0.01% 3106

Other funds holding HRMY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Royce & Associates
Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Nuveen's HRMY Position: Q3 2026 in Review

Nuveen increased its Harmony Biosciences (HRMY) stake by 1.5% in Q3 2026, buying an estimated $52.3K and bringing the position to 91,232 shares worth $3.58M. The position accounts for ﹤0.01% of the portfolio, ranked #2282.

Nuveen first reported a position in HRMY in Q4 2020 and has held it in 24 quarters since. The position peaked at $24.1M in Q2 2022. 178 funds tracked by Wall St. Rank hold HRMY as of Q3 2026.

  • Nuveen held 91,232 shares of Harmony Biosciences worth $3.58M as of Q3 2026.
  • Nuveen bought 1,354 Harmony Biosciences shares in Q3 2026, an estimated $52.3K.
  • Harmony Biosciences made up ﹤0.01% of Nuveen's portfolio in Q3 2026, its #2282 holding.
  • Nuveen first reported a position in Harmony Biosciences in Q4 2020 and has held it in 24 quarters since.
  • Nuveen's Harmony Biosciences position peaked at $24.1M in Q2 2022.
  • 178 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2026.

Based on Nuveen's 13F filing for Q3 2026, filed 10 Nov 2026.